Phase 2 Trial Recruiting: WOMBAT Study on Bipolar Androgen Therapy for Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxPhase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 1/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune Cells
/in Clinical Trial, Not PCa related/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/in Clinical Trial, Metastatic, Phase 1/by MaxXaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: AVA6000 Targeted Chemotherapy for FAP-Positive Tumors (Including Prostate Cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
- Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors April 20, 2026